CLINICAL EVALUATION OF OMICRON SUBVARIANT BA. 2- A HOSPITAL BASED STUDY
DOI:
https://doi.org/10.55489/njmr.13022023953Keywords:
SARSCOV-2, Fever, BA.2, Omicron, RTPCR, Clinical evaluationAbstract
Introduction- Omicron is subdivided into BA.1 and BA.2. BA.2 appears to be more transmissible by nature. The new BA.2 sub variant is 30% easier to spread than the original omicron variant. Among those who are infected, headache, sore/itchy throat, sneezing, runny nose, and general body soreness are the most prevalent symptoms. Dizziness and fatigue are two more Omicron BA.2 sub variant symptoms. The aim of the study to evaluate the clinical variability of the BA. 2 sub variant.
Material and methods- A retrospective study was conducted from December 2021 – March 2022 at VRDL, department of microbiology, R. G Kar medical college and hospital. Clinical features, demographic status, comorbidity status was evaluated.
Result - Common symptoms of BA.2 variants are headache, sore throat, fever, muscle pain shortness of breath, runny nose, fatigue, loss of taste, chest pain, diarrhea. Other unusual symptoms are chills, altered smell, eye soreness, swollen glands, rash, hoarse voice. The risk of severe disease was similarly lower for unvaccinated cases during the Omicron period, but it remained high for older persons and middle-aged men with comorbidities. Hospitalization was rare for this variant but affected more the unvaccinated infant group. However, future evolution of the BA.2 sub variant, as well as potential emergent sub variants, should be properly monitored.
References
1. Goutam Mukherjee A, Ramesh Wanjari U, Murali R, Chaudhary U, Renu K, Madhyastha H, et al. Omicron variant infection and the associated immunological scenario. Im-munobiology. 2022 May;227(3):152222. Doi: https://doi.org/10.1016/j.imbio.2022.152222 PMid:35533536 PMCid:PMC9065598
2. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet Lond Engl. 2022 Jan 29;399(10323):437-46. Doi: https://doi.org/10.1016/S0140-6736(22)00017-4 PMid:35065011
3. Li X, Wu L, Qu Y, Cao M, Feng J, Huang H, et al. Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children. Signal Transduct Target Ther. 2022 Jun 28;7(1):203. Doi: https://doi.org/10.1038/s41392-022-01023-w PMid:35764610 PMCid:PMC9240082
4. Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and Decem-ber 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-23. Doi: https://doi.org/10.15585/mmwr.mm7106e2 PMid:35143466 PMCid:PMC8830624
5. Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influ-enza and parainfluenza infections. Emerg Microbes Infect. 2022 Dec;11(1):1742-50. Doi: https://doi.org/10.1080/22221751.2022.2093135 PMid:35730665 PMCid:PMC9258055
6. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2022 Mar;116:38-42. Doi: https://doi.org/10.1016/j.ijid.2021.12.357 PMid:34971823 PMCid:PMC8713416
7. Tabatabai M, Juarez PD, Matthews-Juarez P, Wilus DM, Ramesh A, Alcendor DJ, et al. An Analysis of COVID-19 Mortality During the Dominancy of Alpha, Delta, and Omi-cron in the USA. J Prim Care Community Health. 2023;14: 21501319231170164. Doi: https://doi.org/10.1177/21501319231170164 PMid:37083205 PMCid:PMC10125879
8. Albreiki M, Mousa M, Azman SK, Vurivi H, Alhalwachi Z, Alshehhi F, et al. Risk of hospitalization and vaccine effec-tiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks. Front Immunol. 2023;14:1049393. Doi: https://doi.org/10.3389/fimmu.2023.1049393 PMid:36860855 PMCid:PMC9969353
9. Wu Q, Wang H, Cai J, Ai J, Li Y, Zhang H, et al. Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai. Emerg Microbes Infect. 2023 Dec;12(1):e2169197. Doi: https://doi.org/10.1080/22221751.2023.2169197 PMid:36644859 PMCid:PMC9888446
10. Bonsignore M, Hohenstein S, Kodde C, Leiner J, Schwegmann K, Bollmann A, et al. The Disease Course of Hospitalized COVID-19 Patients During the Delta and Omi-cron Periods in Consideration of Vaccination Status. Dtsch Arzteblatt Int. 2022 Sep 5;119(35-36):605-6. Doi: https://doi.org/10.3238/arztebl.m2022.0263
11. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and Outcomes of Hospitalized Pa-tients in South Africa During the COVID-19 Omicron Wave Compared with Previous Waves. JAMA. 2022 Feb 8;327(6): 583-4. Doi: https://doi.org/10.1001/jama.2021.24868 PMid:34967859 PMCid:PMC8719272
12. Hilbold E, Bär C, Thum T. COVID-19: Insights into long-term manifestations and lockdown impacts. J Sport Health Sci. 2023 Mar 2;S2095-2546(23)00019-4. Doi: https://doi.org/10.1016/j.jshs.2023.02.006 PMid:36868374 PMCid:PMC9977467
13. Strasser ZH, Greifer N, Hadavand A, Murphy SN, Estiri H. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severi-ty in New England. JAMA Netw Open. 2022 Oct 25;5(10): e2238354-e2238354. Doi: https://doi.org/10.1001/jamanetworkopen.2022.38354 PMid:36282501 PMCid:PMC9597387
14. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospi-talisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a co-hort study. The Lancet. 2022 Apr 2;399 (10332):1303-12. Doi: https://doi.org/10.1016/S0140-6736(22)00462-7 PMid:35305296
15. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-52. Doi: https://doi.org/10.15585/mmwr.mm7104e4 PMid:35085225 PMCid:PMC9351529
16. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from COVID infection in pediat-ric and adult patients before and after the emergence of Omicron. MedRxiv Prepr Serv Health Sci. 2022 Jan 2;2021. 12.30.21268495. Doi: https://doi.org/10.1101/2021.12.30.21268495
17. Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J. 2022 Sep 8;19(1):144. Doi: https://doi.org/10.1186/s12985-022-01873-4 PMid:36076271 PMCid:PMC9452867
18. Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023 Apr 18;S2352-4642(23)00078-0. Doi: https://doi.org/10.1016/S2352-4642(23)00078-0 PMid:37084750
19. Mahase E. Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern. BMJ. 2021 Dec 24;375:n3151. Doi: https://doi.org/10.1136/bmj.n3151 PMid:34952835
20. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccina-tion status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2022 Mar;27(9):2200121. Doi: https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121
21. Zhang S, Yang Z, Li ZN, Chen ZL, Yue SJ, Fu RJ, et al. Are Older People Really More Susceptible to SARS-CoV-2? Aging Dis. 2022 Oct 1;13(5):1336-47. Doi: https://doi.org/10.14336/AD.2022.0130 PMid:36186126 PMCid:PMC9466979
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pratiti Datta, Reena Ray Ghosh, Niramoy Maji, Utpal Dan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Author/s retain the copyright of their article, with first publication rights granted to Medsci Publications.
